People starting Ozempic usually ask two things about alcohol: whether they can drink, and whether the drug changes how much they want to.
The label answers the first only indirectly. Trials in people with alcohol use disorder speak to the second. A parallel page covers tirzepatide and alcohol.
What the labels say
The Ozempic label mentions alcohol only in its injection steps, as an alcohol swab [1]. The Wegovy label does the same, plus a liver disease name [2]. Neither gives a limit or a warning about drinking.
That is not the same as saying drinking has no bearing. Three of their warnings are where it matters.
Pancreatitis is the first. The Ozempic label says to watch for persistent or severe belly pain, sometimes spreading to the back, and to stop the drug if pancreatitis is suspected [1].
Low blood sugar is the second. The label warns the risk rises when semaglutide is used with insulin or a sulfonylurea, and a lower dose of those drugs may be needed.
Fluid loss is the third. The Wegovy label warns that nausea, vomiting and diarrhea can dehydrate you enough to harm the kidneys [2].
Does semaglutide change drinking? The trials
Three randomized, placebo-controlled trials of semaglutide in adults with alcohol use disorder are summarized below. They differ in dose, length and who took part.
| Trial | Who and how long | Dose | Main result |
|---|---|---|---|
| Hendershot 2025 | 48 adults not seeking treatment, 9 weeks | 0.25 mg rising to 1.0 mg weekly | Less alcohol drunk in a lab session; no change in drinking days |
| Klausen 2026 | 108 adults seeking treatment, with obesity, 26 weeks | 2.4 mg weekly plus therapy | Heavy drinking days fell 13.7 points more than placebo |
| Schacht 2026 | 50 adults seeking treatment, 8 weeks | Oral, 3 mg then 7 mg daily | Fewer heavy drinking days; no change in lab craving |
In the first trial, low doses reduced grams of alcohol drunk in a lab session (β −0.48)[4]. Drinks per drinking day and weekly craving also fell, but drinks per calendar day and number of drinking days did not.
The largest trial used the full weight-loss dose alongside cognitive behavioral therapy [5]. Heavy drinking days fell by 41.1 percentage points on semaglutide, against 26.4 on placebo.
That is a difference of 13.7 points (95% CI −22.0 to −5.4). Side effects were mostly mild to moderate stomach and bowel effects, more common on semaglutide.
The oral trial missed its primary outcome, craving measured in the lab [6]. It also found no change in drinks per day. Heavy drinking days, drinks per drinking day and everyday craving all fell.
What records of real patients show
Two large record studies point the same way, with the usual limit: they show associations, not cause.
In health records of 83,825 people with obesity, semaglutide was linked to a 50% to 56% lower risk of a new or recurrent alcohol use disorder diagnosis over 12 months [7]. The comparison was other obesity drugs.
A Swedish national study followed 227,866 people with alcohol use disorder [8]. Periods on semaglutide carried a lower risk of hospital care for it (adjusted hazard ratio 0.64) than periods off it.
Putting it together
The labels set no drinking limit, and neither does this page. The advisory’s advice is to minimize alcohol on these drugs, mainly because of stomach side effects.
Semaglutide is not approved to treat alcohol use disorder. The trial results are real but mixed across outcomes, and two of the three trials ran 9 weeks or less.
The full list of side effects is in semaglutide side effects. Eating patterns that ease stomach effects are in what to eat on semaglutide. To compare prescribers, see the compounded semaglutide rankings.